Skip to main content

Phospho AKT1 antibody pS473 [EP2109Y] ab81283 is a rabbit monoclonal antibody that is used in AKT1 western blotting and IHC. Suitable for human, mouse and rat samples.

- Recombinant format for unrivaled batch-batch consistency: no need for same-lot requests
- Antibody clone EP2109Y has been tried and trusted by researchers since 2009 and is cited in >730 publications
- Specificity and sensitivity confirmed in IHC with multi-tissue microarray (TMA) validation
New 20 ul size available


Images

Western blot - Anti-AKT1 (phospho S473) antibody [EP2109Y] (AB81283), expandable thumbnail
  • Western blot - Anti-AKT1 (phospho S473) antibody [EP2109Y] (AB81283), expandable thumbnail
  • Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-AKT1 (phospho S473) antibody [EP2109Y] (AB81283), expandable thumbnail
  • Western blot - Anti-AKT1 (phospho S473) antibody [EP2109Y] (AB81283), expandable thumbnail
  • Dot Blot - Anti-AKT1 (phospho S473) antibody [EP2109Y] (AB81283), expandable thumbnail

Publications

Key facts

Isotype

IgG

Host species

Rabbit

Storage buffer

pH: 7.2 - 7.4
Preservative: 0.01% Sodium azide
Constituents: 59% PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA

Form

Liquid

Clonality

Monoclonal

Immunogen

  • The exact immunogen used to generate this antibody is proprietary information.

Reactivity data

Select an application
Product promiseTestedExpectedPredictedNot recommended
IHC-PDotWBIn-Cell ELISAICC/IFFlow CytIP
Human
Tested
Expected
Tested
Expected
Not recommended
Not recommended
Not recommended
Mouse
Expected
Expected
Tested
Tested
Not recommended
Not recommended
Not recommended
Rat
Expected
Expected
Tested
Expected
Not recommended
Not recommended
Not recommended
Synthetic peptide
Not recommended
Tested
Not recommended
Not recommended
Not recommended
Not recommended
Not recommended

Tested
Tested

Species

Human

Dilution info

1/100 - 1/250

Notes

Perform heat-mediated antigen retrieval before commencing with IHC staining protocol.

Expected
Expected

Species

Mouse, Rat

Dilution info

Use at an assay dependent concentration.

Notes

-

Not recommended
Not recommended

Species

Synthetic peptide

Dilution info

-

Notes

-

Tested
Tested

Species

Synthetic peptide

Dilution info

1/1000

Notes

-

Expected
Expected

Species

Human, Mouse, Rat

Dilution info

Use at an assay dependent concentration.

Notes

-

Tested
Tested

Species

Human

Dilution info

1/5000 - 1/10000

Notes

Abcam recommends using BSA as the blocking agent.

Species

Mouse

Dilution info

1/5000 - 1/10000

Notes

Abcam recommends using BSA as the blocking agent.

Species

Rat

Dilution info

1/5000 - 1/10000

Notes

Abcam recommends using BSA as the blocking agent.

Not recommended
Not recommended

Species

Synthetic peptide

Dilution info

-

Notes

-

Tested
Tested

Species

Mouse

Dilution info

-

Notes

-

Expected
Expected

Species

Human, Rat

Dilution info

Use at an assay dependent concentration.

Notes

-

Not recommended
Not recommended

Species

Synthetic peptide

Dilution info

-

Notes

-

Not recommended
Not recommended

Species

Human, Mouse, Rat, Synthetic peptide

Dilution info

-

Notes

-

Not recommended
Not recommended

Species

Human, Mouse, Rat, Synthetic peptide

Dilution info

-

Notes

-

Not recommended
Not recommended

Species

Mouse, Human, Rat, Synthetic peptide

Dilution info

-

Notes

-

Associated Products

Select an associated product type

12 products for Alternative Product

Target data

Function

AKT1 is one of 3 closely related serine/threonine-protein kinases (AKT1, AKT2 and AKT3) called the AKT kinase, and which regulate many processes including metabolism, proliferation, cell survival, growth and angiogenesis (PubMed:11882383, PubMed:15526160, PubMed:15861136, PubMed:21432781, PubMed:21620960, PubMed:31204173). This is mediated through serine and/or threonine phosphorylation of a range of downstream substrates (PubMed:11882383, PubMed:15526160, PubMed:21432781, PubMed:21620960, PubMed:31204173). Over 100 substrate candidates have been reported so far, but for most of them, no isoform specificity has been reported (PubMed:11882383, PubMed:15526160, PubMed:21432781, PubMed:21620960). AKT is responsible of the regulation of glucose uptake by mediating insulin-induced translocation of the SLC2A4/GLUT4 glucose transporter to the cell surface (By similarity). Phosphorylation of PTPN1 at 'Ser-50' negatively modulates its phosphatase activity preventing dephosphorylation of the insulin receptor and the attenuation of insulin signaling (By similarity). Phosphorylation of TBC1D4 triggers the binding of this effector to inhibitory 14-3-3 proteins, which is required for insulin-stimulated glucose transport (PubMed:11994271). AKT regulates also the storage of glucose in the form of glycogen by phosphorylating GSK3A at 'Ser-21' and GSK3B at 'Ser-9', resulting in inhibition of its kinase activity (By similarity). Phosphorylation of GSK3 isoforms by AKT is also thought to be one mechanism by which cell proliferation is driven (By similarity). AKT regulates also cell survival via the phosphorylation of MAP3K5 (apoptosis signal-related kinase) (PubMed:11154276). Phosphorylation of 'Ser-83' decreases MAP3K5 kinase activity stimulated by oxidative stress and thereby prevents apoptosis (PubMed:11154276). AKT mediates insulin-stimulated protein synthesis by phosphorylating TSC2 at 'Ser-939' and 'Thr-1462', thereby activating the mTORC1 signaling pathway, and leading to both phosphorylation of 4E-BP1 and in activation of RPS6KB1 (PubMed:12150915, PubMed:12172553). Also regulates the mTORC1 signaling pathway by catalyzing phosphorylation of CASTOR1 and DEPDC5 (PubMed:31548394, PubMed:33594058). AKT is involved in the phosphorylation of members of the FOXO factors (Forkhead family of transcription factors), leading to binding of 14-3-3 proteins and cytoplasmic localization (PubMed:10358075). In particular, FOXO1 is phosphorylated at 'Thr-24', 'Ser-256' and 'Ser-319' (PubMed:10358075). FOXO3 and FOXO4 are phosphorylated on equivalent sites (PubMed:10358075). AKT has an important role in the regulation of NF-kappa-B-dependent gene transcription and positively regulates the activity of CREB1 (cyclic AMP (cAMP)-response element binding protein) (PubMed:9829964). The phosphorylation of CREB1 induces the binding of accessory proteins that are necessary for the transcription of pro-survival genes such as BCL2 and MCL1 (PubMed:9829964). AKT phosphorylates 'Ser-454' on ATP citrate lyase (ACLY), thereby potentially regulating ACLY activity and fatty acid synthesis (By similarity). Activates the 3B isoform of cyclic nucleotide phosphodiesterase (PDE3B) via phosphorylation of 'Ser-273', resulting in reduced cyclic AMP levels and inhibition of lipolysis (By similarity). Phosphorylates PIKFYVE on 'Ser-318', which results in increased PI(3)P-5 activity (By similarity). The Rho GTPase-activating protein DLC1 is another substrate and its phosphorylation is implicated in the regulation cell proliferation and cell growth (By similarity). AKT plays a role as key modulator of the AKT-mTOR signaling pathway controlling the tempo of the process of newborn neurons integration during adult neurogenesis, including correct neuron positioning, dendritic development and synapse formation (By similarity). Signals downstream of phosphatidylinositol 3-kinase (PI(3)K) to mediate the effects of various growth factors such as platelet-derived growth factor (PDGF), epidermal growth factor (EGF), insulin and insulin-like growth factor 1 (IGF1) (PubMed:12176338, PubMed:12964941). AKT mediates the antiapoptotic effects of IGF1 (By similarity). Essential for the SPATA13-mediated regulation of cell migration and adhesion assembly and disassembly (PubMed:19934221). May be involved in the regulation of the placental development (By similarity). Phosphorylates STK4/MST1 at 'Thr-120' and 'Thr-387' leading to inhibition of its: kinase activity, nuclear translocation, autophosphorylation and ability to phosphorylate FOXO3 (PubMed:17726016). Phosphorylates STK3/MST2 at 'Thr-117' and 'Thr-384' leading to inhibition of its: cleavage, kinase activity, autophosphorylation at Thr-180, binding to RASSF1 and nuclear translocation (PubMed:20086174). Phosphorylates SRPK2 and enhances its kinase activity towards SRSF2 and ACIN1 and promotes its nuclear translocation (PubMed:19592491). Phosphorylates RAF1 at 'Ser-259' and negatively regulates its activity (PubMed:10576742). Phosphorylation of BAD stimulates its pro-apoptotic activity (PubMed:10926925). Phosphorylates KAT6A at 'Thr-369' and this phosphorylation inhibits the interaction of KAT6A with PML and negatively regulates its acetylation activity towards p53/TP53 (PubMed:23431171). Phosphorylates palladin (PALLD), modulating cytoskeletal organization and cell motility (PubMed:20471940). Phosphorylates prohibitin (PHB), playing an important role in cell metabolism and proliferation (PubMed:18507042). Phosphorylates CDKN1A, for which phosphorylation at 'Thr-145' induces its release from CDK2 and cytoplasmic relocalization (PubMed:16982699). These recent findings indicate that the AKT1 isoform has a more specific role in cell motility and proliferation (PubMed:16139227). Phosphorylates CLK2 thereby controlling cell survival to ionizing radiation (PubMed:20682768). Phosphorylates PCK1 at 'Ser-90', reducing the binding affinity of PCK1 to oxaloacetate and changing PCK1 into an atypical protein kinase activity using GTP as donor (PubMed:32322062). Also acts as an activator of TMEM175 potassium channel activity in response to growth factors: forms the lysoK(GF) complex together with TMEM175 and acts by promoting TMEM175 channel activation, independently of its protein kinase activity (PubMed:32228865). Acts as a regulator of mitochondrial calcium uptake by mediating phosphorylation of MICU1 in the mitochondrial intermembrane space, impairing MICU1 maturation (PubMed:30504268). Acts as an inhibitor of tRNA methylation by mediating phosphorylation of the N-terminus of METTL1, thereby inhibiting METTL1 methyltransferase activity (PubMed:15861136). In response to LPAR1 receptor pathway activation, phosphorylates Rabin8/RAB3IP which alters its activity and phosphorylates WDR44 which induces WDR44 binding to Rab11, thereby switching Rab11 vesicular function from preciliary trafficking to endocytic recycling (PubMed:31204173).

Alternative names

Recommended products

Phospho AKT1 antibody pS473 [EP2109Y] ab81283 is a rabbit monoclonal antibody that is used in AKT1 western blotting and IHC. Suitable for human, mouse and rat samples.

- Recombinant format for unrivaled batch-batch consistency: no need for same-lot requests
- Antibody clone EP2109Y has been tried and trusted by researchers since 2009 and is cited in >730 publications
- Specificity and sensitivity confirmed in IHC with multi-tissue microarray (TMA) validation
New 20 ul size available

Key facts

Isotype

IgG

Form

Liquid

Clonality

Monoclonal

Immunogen
  • The exact immunogen used to generate this antibody is proprietary information.
Clone number

EP2109Y

Purification technique

Affinity purification Protein A

Specificity

AKT1 (phospho S473) antibody (ab81283) detects AKT1 phosphorylated at Serine 473. The region of AKT1 surrounding S473 has a high degree of similarity to the corresponding regions in AKT2 and AKT3 and thus may cross react with these proteins if phosphorylated on the corresponding serine residue.

Concentration
Loading...

Storage

Shipped at conditions

Blue Ice

Appropriate short-term storage duration

1-2 weeks

Appropriate short-term storage conditions

+4°C

Appropriate long-term storage conditions

-20°C

Aliquoting information

Upon delivery aliquot

Storage information

Avoid freeze / thaw cycle

Notes

Abcam recommended secondaries - Goat Anti-Rabbit HRP (Goat Anti-Rabbit IgG H&L (HRP) ab205718) and Goat Anti-Rabbit Alexa Fluor® 488 (Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) ab150077). Or search our wide range of secondary antibodies for use with your experiment.

Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.

This product is a recombinant monoclonal antibody, which offers several advantages including:

  • - High batch-to-batch consistency and reproducibility
  • - Improved sensitivity and specificity
  • - Long-term security of supply
  • - Animal-free batch production

For more information, read more on recombinant antibodies.

Supplementary info

This supplementary information is collated from multiple sources and compiled automatically.

Activity summary

AKT1 also known as Protein Kinase B (PKB) is a serine/threonine kinase involved in various cellular processes. AKT1 plays an important role in mediating signals for cell survival growth and metabolism. This protein has a molecular weight of approximately 56 kDa. AKT1 is ubiquitously expressed in many tissues including the brain heart and lungs showing its importance in multiple physiological contexts. Phosphorylation of AKT1 at serine 473 denoted as p-AKT S473 is an important modification that regulates its activity.

Biological function summary

AKT1 regulates a broad spectrum of cellular functions through signaling pathways. It is an important player in the phosphatidylinositol 3-kinase (PI3K) and AKT pathway forming part of a complex involved in promoting cell survival and growth. AKT1 interacts closely with other proteins such as mTOR influencing cellular metabolism and autophagy. The phosphorylation state of AKT1 is critical for its activity with modifications like p-AKT S473 impacting its interaction with cellular substrates.

Pathways

AKT1 participates in the PI3K/AKT/mTOR signaling cascade instrumental in cell proliferation and metabolism. AKT1 integrates signals from insulin and growth factors modulating pathways that control cell growth and glucose uptake. This pathway involves proteins like mTOR and phospho-AKT which coordinate cellular responses to external stimuli. AKT1’s phosphorylation at serine 473 and the involvement of AKT1 E17K a gain-of-function mutation influence these pathways significantly.

Associated diseases and disorders

AKT1 has associations with cancer and metabolic disorders. Dysregulation of the PI3K/AKT/mTOR pathway involving AKT1 and mTOR often results in oncogenic transformation and uncontrolled cellular proliferation. In cancer such as breast cancer AKT1 mutations including AKT1 E17K are implicated altering cell signals for growth. Additionally AKT1 is connected to metabolic disorders such as Type 2 diabetes where it affects insulin signaling and glucose metabolism highlighting its interaction with metabolic proteins like mTOR and phospho-AKT.

Product promise

We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.

In the unlikely event of one of our products not working as expected, you are covered by our product promise.

Full details and terms and conditions can be found here:
Terms & Conditions.

12 product images

  • Western blot - Anti-AKT1 (phospho S473) antibody [EP2109Y] (ab81283), expandable thumbnail

    Western blot - Anti-AKT1 (phospho S473) antibody [EP2109Y] (ab81283)

    Blocking buffer and concentration: 5% NFDM/TBST

    All lanes: Western blot - Anti-AKT1 (phospho S473) antibody [EP2109Y] (ab81283) at 1/25000 dilution

    Lane 1: NIH/3T3 (Mouse embryonic fibroblast) treated with 100ng/ml PDGF for 1 hour whole cell lysates at 15 µg

    Lane 2: NIH/3T3 (Mouse embryonic fibroblast) whole cell lysates at 15 µg

    Secondary

    All lanes: Western blot - Goat Anti-Rabbit IgG H&L (HRP) (Goat Anti-Rabbit IgG H&L (HRP) ab97051) at 1/20000 dilution

    Predicted band size: 55 kDa

    Observed band size: 56 kDa

    Exposure time: 3min

  • Western blot - Anti-AKT1 (phospho S473) antibody [EP2109Y] (ab81283), expandable thumbnail

    Western blot - Anti-AKT1 (phospho S473) antibody [EP2109Y] (ab81283)

    The basal expression level of AKT1 (phospho S473) varies in different cell lines reported by PMID: 19372546. But to detect clear signal, treatment is strongly recommended when using this antibody.

    Blocking and diluting buffer: 5% NFDM/TBST

    All lanes: Western blot - Anti-AKT1 (phospho S473) antibody [EP2109Y] (ab81283) at 1/1000 dilution

    Lane 1: LNCaP (Human prostate carcinoma epithelial cell) whole cell lysates at 20 µg

    Lane 2: LNCaP (Human prostate carcinoma epithelial cell) treated with 0.1 uM Calyculin A for 30 minutes whole cell lysates at 20 µg

    Lane 3: A549 (Human lung carcinoma epithelial cell) whole cell lysates at 20 µg

    Lane 4: MCF7 (Human breast adenocarcinoma epithelial cell) whole cell lysates at 20 µg

    Lane 5: HepG2 (Human hepatocellular carcinoma epithelial cell) whole cell lysates at 20 µg

    Lane 6: HUVEC (Human umbilical vein endothelial cell) whole cell lysates at 20 µg

    Lane 7: C2C12 (Mouse myoblasts myoblast) whole cell lysates at 20 µg

    Lane 8: Mouse brain lysates at 20 µg

    Lane 9: Rat heart lysates at 20 µg

    Secondary

    All lanes: Western blot - Goat Anti-Rabbit IgG H&L (HRP) (Goat Anti-Rabbit IgG H&L (HRP) ab97051) at 1/20000 dilution

    Predicted band size: 55 kDa

    Exposure time: 50s

  • Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-AKT1 (phospho S473) antibody [EP2109Y] (ab81283), expandable thumbnail

    Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-AKT1 (phospho S473) antibody [EP2109Y] (ab81283)

    ab81283, at 1/100 dilution, staining AKT1 in untreated (left panel) and Phosphatase-treated (right panel) human cervical carcinoma by Immunohistochemistry using formalin-fixed, paraffin-embedded tissue

    Perform heat mediated antigen retrieval before commencing with IHC staining protocol.

  • Western blot - Anti-AKT1 (phospho S473) antibody [EP2109Y] (ab81283), expandable thumbnail

    Western blot - Anti-AKT1 (phospho S473) antibody [EP2109Y] (ab81283)

    Blocking and diluting buffer: 5% NFDM/TBST.

    All lanes: Western blot - Anti-AKT1 (phospho S473) antibody [EP2109Y] (ab81283) at 0.259 µg/mL

    Lane 1: HeLa (human cervix adenocarcinoma epithelial cell) grown in serum free media overnight, whole cell lysate at 10 µg

    Lane 2: HeLa grown in serum free media overnight, then treated with 150nM Insulin for 5min, whole cell lysate at 10 µg

    Lane 3: HeLa grown in serum free media overnight, then treated with 150nM Insulin for 5min, whole cell lysate. Then the membrane was incubated with alkaline phosphatase at 10 µg

    Secondary

    All lanes: Western blot - Goat Anti-Rabbit IgG H&L (HRP) (Goat Anti-Rabbit IgG H&L (HRP) ab97051) at 1/20000 dilution

    Predicted band size: 55 kDa

  • Dot Blot - Anti-AKT1 (phospho S473) antibody [EP2109Y] (ab81283), expandable thumbnail

    Dot Blot - Anti-AKT1 (phospho S473) antibody [EP2109Y] (ab81283)

    Dot blot analysis of AKT1 (phospho S473) phospho peptide (Lane 1) and AKT1 non-phospho peptide (Lane 2) labelling AKT1 (phospho S473) phospho peptide with ab81283 at a dilution of 1:1000 dilution (0.259μg/ml). A Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated (Goat Anti-Rabbit IgG H&L (HRP) ab97051) was used as the secondary antibody at a dilution of 1:20,000 dilution.

    Blocking buffer: 5% NFDM/TBST. Dilution buffer: 5% NFDM /TBST.

  • In-Cell ELISA - Anti-AKT1 (phospho S473) antibody [EP2109Y] (ab81283), expandable thumbnail

    In-Cell ELISA - Anti-AKT1 (phospho S473) antibody [EP2109Y] (ab81283)

    NIH3T3 cells were starved overnight and treated with PDGF 50ng/mL or vehicle control for 1 hour prior to fixation with 4% paraformaldehyde. Levels of total Akt were measured using antibody ab81283 on an infrared in cell ELISA assay platform.

  • Western blot - Anti-AKT1 (phospho S473) antibody [EP2109Y] (ab81283), expandable thumbnail

    Western blot - Anti-AKT1 (phospho S473) antibody [EP2109Y] (ab81283)

    Blocking and diluting buffer: 5% NFDM/TBST.

    All lanes: Western blot - Anti-AKT1 (phospho S473) antibody [EP2109Y] (ab81283) at 0.259 µg/mL

    Lane 1: LNCaP (human prostate carcinoma epithelial cell) whole cell lysate at 10 µg

    Lane 2: LNCaP treated with 100nM Cacyculin A for 30min whole cell lysate at 10 µg

    Lane 3: LNCaP treated with 100nM Cacyculin A for 30min whole cell lysate. Then the membrane was incubated with alkaline phosphatase at 10 µg

    Secondary

    All lanes: Western blot - Goat Anti-Rabbit IgG H&L (HRP) (Goat Anti-Rabbit IgG H&L (HRP) ab97051) at 1/20000 dilution

    Predicted band size: 55 kDa

  • Western blot - Anti-AKT1 (phospho S473) antibody [EP2109Y] (ab81283), expandable thumbnail

    Western blot - Anti-AKT1 (phospho S473) antibody [EP2109Y] (ab81283)

    Insulin treatment: cells were starved overnight and then treated for 20 min (Insulin) at 100 ng/ml.

    Phosphatase treatment: membrane strips were incubated with 200 ul of phosphatase (150 U/ml) at 37 degrees for 1 hour.

    All lanes: Western blot - Anti-AKT1 (phospho S473) antibody [EP2109Y] (ab81283) at 1/1000 dilution

    All lanes: HEK293 cell lysate

    Predicted band size: 55 kDa

  • Western blot - Anti-AKT1 (phospho S473) antibody [EP2109Y] (ab81283), expandable thumbnail

    Western blot - Anti-AKT1 (phospho S473) antibody [EP2109Y] (ab81283)

    PDGF treatment: cells were starved overnight and then treated for 1 h with PDGF at 100 ng/ml.

    Phosphatase treatment: membrane strips were incubated with 200 ul of phosphatase (150 U/ml) at 37 degrees for 1 hour.

    All lanes: Western blot - Anti-AKT1 (phospho S473) antibody [EP2109Y] (ab81283) at 1/1000 dilution

    All lanes: NIH/3T3 cell lysate

    Predicted band size: 55 kDa

  • Western blot - Anti-AKT1 (phospho S473) antibody [EP2109Y] (ab81283), expandable thumbnail

    Western blot - Anti-AKT1 (phospho S473) antibody [EP2109Y] (ab81283)

    Primary : All Lanes : Anti AKT1 (phospho S473) antibody (ab81283) at 1:5000 dilution. Lane 1 = AKT1 (His tag) full length recombinant protein Recombinant human AKT1 protein (Active) ab62279 - 50ng. Lane 2 = NIH3T3 serum starved overnight, 15ug. Lane 3 = NIH3T3 serum starved overnight and treated with PDGF-AB 50ng/mL for 1 hour, 15ug. Secondary : Lanes 1-3 : Goat polyclonal to Rabbit IgG H&L Pre-Adsorbed (HRP) at 1:5000 developed using the ECL technique. Performed under reducing conditions (50mM DTT, Sample heated at 60°C). Predicted band size : 56kDa. Observed band size : 56kDa. Blocking step: 5% Milk in 50mM Tris+0.05% Tween for 1 hour at RT. Primary antibody buffer: 5% BSA in 50mM Tris+0.05% Tween overnight. Secondary antibody buffer: 5% Milk in 50mM Tris+0.05% Tween for 2 hours at RT. Exposure time : 5 minutes

    All lanes: Western blot - Anti-AKT1 (phospho S473) antibody [EP2109Y] (ab81283)

    Predicted band size: 55 kDa

  • Western blot - Anti-AKT1 (phospho S473) antibody [EP2109Y] (ab81283), expandable thumbnail

    Western blot - Anti-AKT1 (phospho S473) antibody [EP2109Y] (ab81283)

    PC12 cells were incubated at 37°C for 24 hours with vehicle control (0 nM) and 1 μM of Galanin (1-15) (porcine, rat) (ab 141152). Decreased expression of AKT1 (phospho S473) (ab81283) in PC12 cells correlates with an increase in Galanin (1-15) (porcine, rat) concentration, as described in literature.

    Whole cell lysates were prepared with RIPA buffer (containing protease inhibitors and sodium orthovanadate), 30μg of each were loaded on the gel and the WB was run under reducing conditions. After transfer the membrane was blocked for an hour using 3% milk before being incubated withab81283at 1 μg/ml andab8227at 1 μg/ml overnight at 4°C. Antibody binding was detected using an anti-rabbit antibody conjugated to HRP (Goat Anti-Rabbit IgG H&L (HRP) ab97051) at 1/10000 and visualised using ECL development solution.

    All lanes: Western blot - Anti-AKT1 (phospho S473) antibody [EP2109Y] (ab81283)

    Developed using the ECL technique.

    Performed under reducing conditions.

    Predicted band size: 55 kDa

    Observed band size: 60 kDa

    Exposure time: 20min

  • Functional Studies - Anti-AKT1 (phospho S473) antibody [EP2109Y] (ab81283), expandable thumbnail

    Functional Studies - Anti-AKT1 (phospho S473) antibody [EP2109Y] (ab81283)

    MCF7 cells were incubated at 37°C for 2 hours with vehicle control (0 μM) and different concentrations of CCCP (ab 141229). Increased expression of AKT1 (phospho S473) (ab81283) in MCF7 cells correlates with an increase in CCCP concentration, as described in literature.

    Whole cell lysates were prepared with RIPA buffer (containing protease inhibitors and sodium orthovanadate), 10μg of each were loaded on the gel and the WB was run under reducing conditions. After transfer the membrane was blocked for an hour using 5% BSA before being incubated with ab81283 at 2 μg/ml and Anti-beta Actin antibody ab8227 at 1 μg/ml overnight at 4°C. Antibody binding was detected using an anti-rabbit antibody conjugated to HRP (Goat Anti-Rabbit IgG H&L (HRP) ab97051) at 1/10000 and visualised using ECL development solution.

Downloads

Product protocols

For this product, it's our understanding that no specific protocols are required. You can:

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com